No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OCX OncoCyte
- 2.4800
- +0.0400+1.64%
Close Apr 26 16:00 ET
- 2.5800
- +0.1000+4.03%
Post 16:39 ET
33.08MMarket Cap-661P/E (TTM)
2.5806High2.4100Low17.70KVolume2.4800Open2.4400Pre Close43.67KTurnover0.31%Turnover RatioLossP/E (Static)13.34MShares6.200052wk High1.62P/B14.12MFloat Cap2.080052wk Low--Dividend TTM5.69MShs Float204.8000Historical High--Div YieldTTM6.99%Amplitude2.0800Historical Low2.4670Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Oncocyte Is Maintained at Buy by Needham
Oncocyte Is Maintained at Buy by Needham
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
Express News | OncoCyte Corp : Needham Raises Target Price to $4.25 From $3.60
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake in OncoCyte Corp as of April 15 - SEC Filing
Comments
Insider buy
$OncoCyte(OCX.US$ Director Arno Andrew purchased 33,898 shares of common stock on Apr 11, 2024 at an average price of $2.95 for a total value of $99,999.1.
Biotech Stocks: Price Action and Logic
I have noticed recently that some shares despite FDA approval, price action is opposite, also earning call sometimes when it beats estimates projection, the market sentiment or price action is in reverse.
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics(ENLV.US$
$Akebia Therapeutics(AKBA.US$
$Rekor Systems(REKR.US$
$OncoCyte(OCX.US$
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics(ENLV.US$
$Akebia Therapeutics(AKBA.US$
$Rekor Systems(REKR.US$
$OncoCyte(OCX.US$
1
2
$OncoCyte(OCX.US$ any chance this will climb back up, considering it has been shorted to oblivion from +90%
1
$OncoCyte(OCX.US$ i will hold till 11:30 and switch to the next surest. this was a trap. stock like this will end up very very very bad next week for folks that expects the remix of earlier today
2
$OncoCyte(OCX.US$ from +90% to -10% lol.. Did the whole company catch fire or the ceos died or this is just some fckd up manipulation?
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg